Neostem's Balancing Act A Boon For Shareholders [View article]
A few weeks ago I wrote about the possibility of a reverse split being a possibility. After reading Dr Smith's recent interview, it is apparent, that it is not happening. The recent developments and announcements on AMR-001, VSEL technology advancements, the retirement of the preferred stock, and the revenue growth of PCT should really be the focus of those investing in NBS, not a reverse split that will not happen.
I will be writing another article on this, since it seems to have stirred up some rumors among investors.
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher [View article]
Hows it a short-term negative? NBS used money in escrow. They were paying investors in equity and have now redeemed the shares. There is no selling pressure. It creates support because there will not be selling pressure on a monthly basis due to the payment of stock
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher [View article]
Neostem is not on a downward trend. A higher stock price will draw more eyes to the stock. With its recent announcements the company should be clear over $1.00, at a higher price I think it would have seen more movement
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher [View article]
I doubt that it was due to anything else. I gave several examples. I also think it depends on the size of a company. If a company does a reverse split and has a market cap of just $50 million then I don't think it matters. But in the case of Neostem, it is already valued at more than $100 million, and is priced cheap compared to biotechnology stocks with similar valuations.
Some investors will not look at a company priced below $1.00, regardless of size or potential, nor will institutional investors. Therefore, it is a perception changer. Your argument is correct, the price of a stock doesn't matter, it's the market capitalization, but because of its psychological impact I do believe it is a catalyst.
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher [View article]
I think that it is fairly valued for the completion of an animal study. I think the company has promise and if it can prove that its cells work in a larger human study then it could become one of the best returns over the next five years.
5 Big Time Biotech Movers On Wednesday [View article]
Based on the fact that I said "10% rally" should indicate that the article was written before its end of the day push. I am not trying to determine whether or not the stock is undervalued or the level of overall upside in shares of ITMN. Perhaps Wednesday was the start of a turnaround, and it will trade higher throughout the remainder of this year, I don't know. I simply mentioned that this is a stock that has traded in a steep downtrend for all of the last year, which is true. The stock briefly traded higher earlier this month following the news of the Canadian approval, which is true. My point was that because of its long-term trend that investors should be careful and understand that it's possible that ITMN was bouncing from the bottom with heavy volume (which did occur) but that it could continue its trend. Obviously the end of day rally, or push with higher volume, is a positive sign for ITMN,, but this had not occurred at the time that I wrote this piece. This is a very volatile stock, but because of its yearly loss it makes sense that rallies would be excessive, and investors should be careful. Hopefully, it reverses from this point and continues to trade higher. But this is a stock with a recent history of decent pops, ever-so-often, only to sell-off. Until a more significant uptrend is realized I would watch it closely. Like I said, hopefully this is the reverse and shareholders of ITMN will finally be rewarded.
A Close Look At Home Depot: Cautiously Optimistic Outlook [View article]
I can also tell a difference in the traffic at local HD stores. It seems that traffic has increased for the last year, but revenue remains near break even. I am curious to see when the company can grow its top line, because I don't think it could squeeze much higher margins.
The Promising, Cheap, And Growing Cell Therapy Arena Continues To Outperform The Market [View article]
The next Apple would be big shoes to follow. I believe it is a massive market and that we will see many approvals over the next five years. I also anticipate large pharma scooping in to buy cell therapy companies once approvals occur
Neostem's Balancing Act A Boon For Shareholders [View article]
I will be writing another article on this, since it seems to have stirred up some rumors among investors.
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher [View article]
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher [View article]
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher [View article]
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher [View article]
Some investors will not look at a company priced below $1.00, regardless of size or potential, nor will institutional investors. Therefore, it is a perception changer. Your argument is correct, the price of a stock doesn't matter, it's the market capitalization, but because of its psychological impact I do believe it is a catalyst.
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher [View article]
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher [View article]
5 Big Time Biotech Movers On Wednesday [View article]
A Close Look At Home Depot: Cautiously Optimistic Outlook [View article]
The Promising, Cheap, And Growing Cell Therapy Arena Continues To Outperform The Market [View article]
The Promising, Cheap, And Growing Cell Therapy Arena Continues To Outperform The Market [View article]
A Close Look At Home Depot: Cautiously Optimistic Outlook [View article]
The Promising, Cheap, And Growing Cell Therapy Arena Continues To Outperform The Market [View article]
The Promising, Cheap, And Growing Cell Therapy Arena Continues To Outperform The Market [View article]
A Gold Mine In Biotechnology: The Companies Poised To Benefit [View article]